Chronic pancreatitis- Pipeline Insight, 2024

Chronic pancreatitis- Pipeline Insight, 2024

DelveInsight’s, “Chronic pancreatitis- Pipeline Insight, 2024” report provides comprehensive insights about 5+companies and 5+pipeline drugs in Chronic pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic pancreatitis: Understanding

Chronic pancreatitis: Overview

Chronic pancreatitis is a condition where the pancreas (a small organ located behind the stomach and below the ribcage) becomes permanently damaged from inflammation. It is a progressive inflammatory disorder that leads to irreversible destruction of exocrine and endocrine pancreatic parenchyma caused by atrophy and/or replacement with fibrotic tissue. Since the main function of the pancreas is to produce digestive enzymes and hormones, such as insulin, that regulate blood sugar levels, and therefore, damage to the pancreas can cause problems with digestion, absorption of nutrients, and production of insulin. As a result, people with chronic pancreatitis can lose weight, experience diarrhea, become malnourished with vitamin deficiencies and can develop diabetes. The main symptom can include abdominal pain and Pancreatic insufficiency. The symptoms can take several years to occur and most cases of chronic pancreatitis are caused by long-standing over use of alcohol. Less common causes of chronic pancreatitis include genetic disorders, such as cystic fibrosis, hereditary pancreatitis, or autoimmune pancreatitis. Rarely, an attack of severe acute pancreatitis causes permanent scarring (fibrosis) of the pancreas that leads to chronic pancreatitis. In some people, chronic pancreatitis develops when the pancreatic duct is blocked (obstructed) by stones or a tumor. The clinical presentation of the patients with chronic pancreatitis, most commonly present with the recurrent episodes of acute pancreatitis. This will often progress to chronic abdominal pain that is characteristically located in the epigastrium and radiates to the back. There is no single test that can be used to diagnose chronic pancreatitis and it is generally made based on a patient's history, clinical presentation, and imaging findings. Diagnosing chronic pancreatitis in its early stages is often difficult. Many pancreatic cells can be damaged before abnormalities show up on tests, X-rays or scans. The diagnostic tests use for the diagnosis include blood tests which will look for high levels of two pancreatic enzymes, amylase and lipase. Apart from this, imaging techniques such as CT scan, ultrasound, and magnetic resonance cholangiopancreatography can also be use in the diagnosis process.

The goals of all treatment modalities include improving the pain, quality of life, and decreased morbidity and mortality from endocrine and exocrine pancreatic dysfunction. Treatment of chronic pancreatitis can be medical, endoscopic, or surgical.

• Medical: For milder types of pain, medications such as acetaminophen (Tylenol) or ibuprofen (Advil, Motrin and others) are use and many people need narcotic medications to control the pain.
• Endoscopy: Endoscopy can be used to treat symptomatic strictures, stones, and pseudocysts. Endoscopic drainage of pseudocysts has a similar rate of pain relief as surgery, with equivalent or lower mortality.
• Surgery: surgical treatment may be an option if the pancreatic ducts are dilated or if there is an inflammatory mass in one region of the pancreas. There are different techniques that remove different amounts of the pancreas. The one chosen depends on the severity of the patient’s condition.

""Chronic pancreatitis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic pancreatitis pipeline landscape is provided which includes the disease overview and Chronic pancreatitis treatment guidelines. The assessment part of the report embraces, in depth Chronic pancreatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic pancreatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic pancreatitis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic pancreatitis.

Chronic pancreatitis: Emerging Drugs Chapters

This segment of the Chronic pancreatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic pancreatitis: Emerging Drugs

• FW-EPI (adrulipase): First Wave BioPharma, Inc.

FW-EPI (adrulipase) is a recombinant lipase enzyme administered as an oral, non-systemic biologic capsule for the treatment of exocrine pancreatic insufficiency (EPI) associated with chronic pancreatitis. Adrulipase is derived from the Yarrowia lipolytica yeast lipase and is designed to break up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients. First Wave is developing adrulipase as a monotherapy and in combination with pancreatic enzyme replacement therapy (PERT). The drug is in Phase II clinical trial of adrulipase in combination with PERT.

• CM4620: calcimedica

CM4620, a novel, calcium release-activated calcium (CRAC) channel inhibitor administered orally. The drug is in pre-clinical stage for the treatment of Chronic Pancreatitis.

Further product details are provided in the report……..

Chronic pancreatitis: Therapeutic Assessment

This segment of the report provides insights about the different Chronic pancreatitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic pancreatitis

There are approx. 5+ key companies which are developing the therapies for Chronic pancreatitis. The companies which have their Chronic pancreatitis drug candidates in the most advanced stage, i.e. phase II include, First Wave BioPharma, Inc.

Phases

DelveInsight’s report covers around 5+products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic pancreatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic pancreatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic pancreatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic pancreatitis drugs.

Chronic pancreatitis: Report Insights

• Chronic pancreatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic pancreatitis: Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic pancreatitis drugs?
• How many Chronic pancreatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic pancreatitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic pancreatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic pancreatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• First Wave BioPharma, Inc.
• calcimedica
• Theraly Fibrosis

Key Products

• FW-EPI (adrulipase)
• CM4620
• TLY012